Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has recently launched a phase Ib/II clinical trial (SYS6090-008) to evaluate the safety, tolerability and efficacy of SYS6090 injection combination treatment in advanced or metastatic colorectal cancer participants.

According to reports, the SYS6090-008 clinical trial launched this time is an open, multi-center phase Ib/II clinical trial. The purpose is to evaluate the safety, tolerability, and efficacy of SYS6090 injection combination therapy in colorectal cancer participants. In the future, based on the results of this study, the company will continue to promote phase III confirmatory clinical studies of SYS6090 injection combined treatment in colorectal cancer participants to further verify the clinical value of the SYS6090 injection combination treatment plan. Currently, the recruitment and screening of participants for the SYS6090-008 study is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.